265 related articles for article (PubMed ID: 27855679)
21. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.
Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD
BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540
[TBL] [Abstract][Full Text] [Related]
22. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018.
Lew FH; McQuown B; Borrego J; Cunningham S; Burgess KE
Vet Comp Oncol; 2019 Dec; 17(4):465-471. PubMed ID: 31069932
[TBL] [Abstract][Full Text] [Related]
23. [
Kollberg P; Almquist H; Bläckberg M; Cwikiel M; Gudjonsson S; Lyttkens K; Patschan O; Liedberg F
Scand J Urol; 2017 Aug; 51(4):308-313. PubMed ID: 28532260
[TBL] [Abstract][Full Text] [Related]
24. c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine.
Weishaar KM; Ehrhart EJ; Avery AC; Charles JB; Elmslie RE; Vail DM; London CA; Clifford CA; Eickhoff JC; Thamm DH
J Vet Intern Med; 2018 Jan; 32(1):394-405. PubMed ID: 29194765
[TBL] [Abstract][Full Text] [Related]
25. A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis.
Tani H; Miyamoto R; Noguchi S; Kurita S; Nagashima T; Michishita M; Yayoshi N; Tamura K; Bonkobara M
BMC Vet Res; 2021 Apr; 17(1):147. PubMed ID: 33827546
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
[TBL] [Abstract][Full Text] [Related]
27. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.
Berger EP; Johannes CM; Jergens AE; Allenspach K; Powers BE; Du Y; Mochel JP; Fox LE; Musser ML
J Vet Intern Med; 2018 Nov; 32(6):2045-2053. PubMed ID: 30307656
[TBL] [Abstract][Full Text] [Related]
28. Clinical experience of MRI in two dogs with muscle-invasive transitional cell carcinoma of the urinary bladder.
Lee K; Choi S; Choi H; Lee Y
J Vet Med Sci; 2016 Sep; 78(8):1351-4. PubMed ID: 27149892
[TBL] [Abstract][Full Text] [Related]
29. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer.
Knapp DW; Glickman NW; Widmer WR; DeNicola DB; Adams LG; Kuczek T; Bonney PL; DeGortari AE; Han C; Glickman LT
Cancer Chemother Pharmacol; 2000; 46(3):221-6. PubMed ID: 11021739
[TBL] [Abstract][Full Text] [Related]
30. Piroxicam, mitoxantrone, and coarse fraction radiotherapy for the treatment of transitional cell carcinoma of the bladder in 10 dogs: a pilot study.
Poirier VJ; Forrest LJ; Adams WM; Vail DM
J Am Anim Hosp Assoc; 2004; 40(2):131-6. PubMed ID: 15007049
[TBL] [Abstract][Full Text] [Related]
31. Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.
Pan X; Tsimbas K; Kurzman ID; Vail DM
Vet Comp Oncol; 2016 Jun; 14(2):202-9. PubMed ID: 24735385
[TBL] [Abstract][Full Text] [Related]
32. Quantitative evaluation of canine urinary bladder transitional cell carcinoma using contrast-enhanced ultrasonography.
Macrì F; Di Pietro S; Mangano C; Pugliese M; Mazzullo G; Iannelli NM; Angileri V; Morabito S; De Majo M
BMC Vet Res; 2018 Mar; 14(1):84. PubMed ID: 29530040
[TBL] [Abstract][Full Text] [Related]
33. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Mohammed SI; Craig BA; Mutsaers AJ; Glickman NW; Snyder PW; deGortari AE; Schlittler DL; Coffman KT; Bonney PL; Knapp DW
Mol Cancer Ther; 2003 Feb; 2(2):183-8. PubMed ID: 12589035
[TBL] [Abstract][Full Text] [Related]
34. Toceranib phosphate-associated nephrotic syndrome in a dog: a case report.
Remerowski SM; Herrera CL; Donnelly LL
BMC Vet Res; 2021 Apr; 17(1):146. PubMed ID: 33827545
[TBL] [Abstract][Full Text] [Related]
35. Retrospective evaluation of toceranib phosphate (Palladia) in the treatment of canine carcinomatosis and mesothelioma.
Hicks KA; Leeper HJ; Curran KM
Vet Comp Oncol; 2024 Jun; 22(2):245-254. PubMed ID: 38622074
[TBL] [Abstract][Full Text] [Related]
36. Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma.
Kim C; Matsuyama A; Mutsaers AJ; Woods JP
Can Vet J; 2017 Oct; 58(10):1059-1064. PubMed ID: 28966355
[TBL] [Abstract][Full Text] [Related]
37. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
Wouda RM; Hocker SE; Higginbotham ML
Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs.
Heaton CM; Fernandes AFA; Jark PC; Pan X
J Vet Intern Med; 2020 Mar; 34(2):873-881. PubMed ID: 31977135
[TBL] [Abstract][Full Text] [Related]
39. Toceranib phosphate in the treatment of canine thyroid carcinoma: 42 cases (2009-2018).
Sheppard-Olivares S; Bello NM; Wood E; Szivek A; Biller B; Hocker S; Wouda RM
Vet Comp Oncol; 2020 Dec; 18(4):519-527. PubMed ID: 32012432
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy with methotrexate, vinblastine, epirubicin and carboplatin (Carbo-MVE) in transitional cell urothelial cancer. A Hellenic Co-Operative Oncology Group study.
Skarlos DV; Aravantinos G; Linardou E; Kostakopoulos CA; Kastriotis I; Christodoulou C; Picramenos D; Giannakakis T; Dimopoulos K; Fountzilas G
Eur Urol; 1997; 31(4):420-7. PubMed ID: 9187901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
